NWK Group’s AbbVie ABBV Stock Holding History

NWK Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-550	Closed	-$60K	–	93
2021 Q1	$60K	Hold	550	–	–	0.03%	100
2020 Q4	$59K	Hold	550	–	–	0.03%	98
2020 Q3	$48K	Sell	550 -44	-7%	-$4.14K	0.02%	99
2020 Q2	$58K	Buy	594 +44	+8%	+$3.87K	0.03%	85
2020 Q1	$42K	Buy	+550	New	+$46.8K	0.04%	87

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

NWK Group's ABBV Position: Q2 2021 in Review

NWK Group sold out of AbbVie (ABBV) in Q2 2021, closing a stake of 550 shares — an estimated $60K sold.

NWK Group first reported a position in ABBV in Q1 2020 and held it in 5 quarters. The position peaked at $60K in Q1 2021. 2,676 funds tracked by Wall St. Rank hold ABBV as of Q2 2021.

NWK Group reported no remaining AbbVie position as of Q2 2021 after selling out during the quarter.
NWK Group sold 550 AbbVie shares in Q2 2021, an estimated $60K.
NWK Group first reported a position in AbbVie in Q1 2020 and held it in 5 quarters.
NWK Group's AbbVie position peaked at $60K in Q1 2021.
2,676 funds tracked by Wall St. Rank held AbbVie as of Q2 2021.

Based on NWK Group's 13F filing for Q2 2021, filed 16 Aug 2021.